Nefazodone

Last updated
Nefazodone
Nefazodone.svg
Nefazodone ball-and-stick model.png
Clinical data
Trade names Serzone, Dutonin, Nefadar, others
Other namesBMY-13754-1; MJ-13754-1; MJ-13754; MS-13754
AHFS/Drugs.com Monograph
MedlinePlus a695005
Pregnancy
category
  • C
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • BR: Class C1 (Other controlled substances) [1]
  • US: ℞-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability 20% (variable) [2]
Protein binding 99% (loosely) [2]
Metabolism Liver (CYP3A4, CYP2D6) [3]
Metabolites • Hydroxynefazodone [2]
• mCPP Tooltip meta-Chlorophenylpiperazine [2]
• p-Hydroxynefazodone [3]
• Triazoledione [2]
Elimination half-life • Nefazodone: 2–4 hours [2]
• Hydroxynefazodone: 1.5–4 hours [2]
• Triazoledione: 18 hours [2]
• mCPP Tooltip meta-Chlorophenylpiperazine: 4–8 hours [2]
Excretion Urine: 55%
Feces: 20–30%
Identifiers
  • 1-(3-[4-(3-chlorophenyl)piperazin-1-yl]propyl)-3-ethyl-4-(2-phenoxyethyl)-1H-1,2,4-triazol-5(4H)-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C25H32ClN5O2
Molar mass 470.01 g·mol−1
3D model (JSmol)
  • Clc4cccc(N3CCN(CCCN1/N=C(\N(C1=O)CCOc2ccccc2)CC)CC3)c4
  • InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3 Yes check.svgY
  • Key:VRBKIVRKKCLPHA-UHFFFAOYSA-N Yes check.svgY
   (verify)

Nefazodone, sold formerly under the brand names Serzone, Dutonin, and Nefadar among others, is an atypical antidepressant medication which is used in the treatment of depression and for other uses. [4] [5] [6] [7] Nefazodone is still available in the United States, [8] but was withdrawn from other countries due to rare liver toxicity. The medication is taken by mouth. [9]

Contents

Side effects of nefazodone include dry mouth, sleepiness, nausea, dizziness, blurred vision, weakness, lightheadedness, confusion, and postural low blood pressure, among others. [9] Rarely, nefazodone can cause serious liver damage, with an incidence of death or liver transplantation of about 1 in every 250,000 to 300,000 patient years. [9] Nefazodone is a phenylpiperazine compound and is related to trazodone. It has been described as a serotonin antagonist and reuptake inhibitor (SARI) due to its combined actions as a potent antagonist of the serotonin 5-HT2A and 5-HT2C receptors and weak serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI).

Nefazodone was introduced for medical use in 1994. [7] [10] [11] Generic versions were introduced in 2003. [12] Serious liver toxicity was first reported with nefazodone in 1998, and it was withdrawn from most markets by 2004. [11] [13] However, as of 2023, it continues to be available in the United States in generic from one manufacturer, Teva Pharmaceuticals [14] and is manufactured in Israel. [15]

Medical uses

Nefazodone is used to treat major depressive disorder, aggressive behavior, anxiety, [16] and panic disorder. [17]

Available forms

Nefazodone is available as 50 mg, 100 mg, 150 mg, 200 mg, and 250 mg tablets for oral ingestion. [18]

Contraindications

Contraindications include the coadministration of terfenadine, astemizole, cisapride, pimozide, or carbamazepine. Nefazodone is contraindicated in patients who were withdrawn from nefazodone because of evident liver injury as well as those that have shown hypersensitivity to the drug, its inactive ingredients, or other phenylpiperazine antidepressants. Furthermore, the coadministration of triazolam and nefazodone should be avoided for all patients, including the elderly, since it causes a significant increase in the plasma level of triazolam and not all commercially available dosage forms of triazolam permit a sufficient dosage reduction. If coadministrated, a 75% reduction in the initial dosage of triazolam is recommended. [18]

Side effects

Common and mild side effects of nefazodone reported in clinical trials more often than placebo include dry mouth (25%), sleepiness (25%), nausea (22%), dizziness (17%), blurred vision (16%), weakness (11%), lightheadedness (10%), confusion (7%), and orthostatic hypotension (5%). Rare and serious adverse reactions may include allergic reactions, fainting, painful/prolonged erection, and jaundice. [9] Nefazodone is not especially associated with increased appetite and weight gain. [19] It is also known for having low levels of sexual side effects in comparisons to SSRIs. [20] [21]

Nefazodone can cause severe liver damage which may lead to the need for liver transplantation or to death. The incidence of severe liver damage is approximately 1 in every 250,000 to 300,000 patient-years. [7] [9] By the time it started to be withdrawn from the markets in 2003, nefazodone had been associated with at least 53 cases of liver injury (of which 11 led to death) in the United States, [22] and 51 cases of liver toxicity (of which 2 led to transplantation) in Canada. [23] [24] In a 2002 Canadian study of 32 cases, it was noted that databases like those used in the study tended to include only a small proportion of suspected drug reactions. [24]

Treatment protocols suggest screening for pre-existing liver disease before initiating nefazodone, and those with known liver disease should not be prescribed nefazodone. If serum AST or serum ALT levels are more than 3 times the upper limit of normal (ULN), treatment should be permanently withdrawn. Enzyme labs should be done every six months, and nefazodone should not be a first-line treatment. [25]

Interactions

Nefazodone is a potent inhibitor of CYP3A4, and may interact adversely with many commonly used medications that are metabolized by CYP3A4. [26] [27] [28]

Pharmacology

Pharmacodynamics

Nefazodone [29]
SiteKi (nM)SpeciesRef
SERT Tooltip Serotonin transporter200–459Human [30] [31]
NET Tooltip Norepinephrine transporter360–618Human [30] [31]
DAT Tooltip Dopamine transporter360Human [30]
5-HT1A 80Human [32]
5-HT2A 26Human [32]
5-HT2C 72Human [33]
α1 5.5–48Human [32] [31]
α1A 48Human [33]
α2 84–640Human [32] [31]
β >10,000Rat [34]
D2 910Human [32]
H1 ≥370Human [32] [33]
mACh Tooltip Muscarinic acetylcholine receptor>10,000Human [32]
Notes: Values are Ki (nM). The smaller the value, the more strongly the drug binds to the site.

Nefazodone acts primarily as a potent antagonist of the serotonin 5-HT2A receptor and to a lesser extent of the serotonin 5-HT2C receptor. [32] It also has high affinity for the α1-adrenergic receptor and serotonin 5-HT1A receptor, and relatively lower affinity for the α2-adrenergic receptor and dopamine D2 receptor. [32] Nefazodone has low but significant affinity for the serotonin, norepinephrine, and dopamine transporters as well, and therefore acts as a weak serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). [30] It has low but potentially significant affinity for the histamine H1 receptor, where it is an antagonist, and hence may have some antihistamine activity. [32] [33] Nefazodone has negligible activity at muscarinic acetylcholine receptors, and accordingly, has no anticholinergic effects. [30]

Pharmacokinetics

The bioavailability of nefazodone is low and variable, about 20%. [2] Its plasma protein binding is approximately 99%, but it is bound loosely. [2]

Nefazodone is metabolized in the liver, with the main enzyme involved thought to be CYP3A4. [3] The drug has at least four active metabolites, which include hydroxynefazodone, para-hydroxynefazodone, triazoledione, and meta-chlorophenylpiperazine (mCPP). [2] Nefazodone has a short elimination half-life of about 2 to 4 hours. [2] Its metabolite hydroxynefazodone similarly has an elimination half-life of about 1.5 to 4 hours, whereas the elimination half-lives of triazoledione and mCPP are longer at around 18 hours and 4 to 8 hours, respectively. [2] Due to its long elimination half-life, triazoledione is the major metabolite and predominates in the circulation during nefazodone treatment, with plasma levels that are 4 to 10 times higher than those of nefazodone itself. [2] [35] Conversely, hydroxynefazodone levels are about 40% of those of nefazodone at steady state. [2] Plasma levels of mCPP are very low at about 7% of those of nefazodone; hence, mCPP is only a minor metabolite. [2] [35] mCPP is thought to be formed from nefazodone specifically by CYP2D6. [3] [35]

The ratios of brain-to-plasma concentrations of mCPP to nefazodone are 47:1 in mice and 10:1 in rats, suggesting that brain exposure to mCPP may be much higher than plasma exposure. [2] Conversely, hydroxynefazodone levels in the brain are 10% of those in plasma in rats. [2] As such, in spite of its relatively low plasma concentrations, brain exposure to mCPP may be substantial, whereas that of hydroxynefazodone may be minimal. [2]

Chemistry

Nefazodone is a phenylpiperazine; [36] it is an alpha-phenoxyl derivative of etoperidone which in turn was a derivative of trazodone. [37]

History

Nefazodone was discovered by scientists at Bristol-Myers Squibb (BMS) who were seeking to improve on trazodone by reducing its sedating qualities. [37]

BMS obtained marketing approvals for nefazodone worldwide, including in the United States and Europe, in 1994. [7] [10] [11] It was marketed in the United States under the brand name Serzone [38] and in Europe under the brand name Dutonin. [39]

The first reports of serious liver toxicity with nefazodone were published in 1998 and 1999. [40] [41] These instances were quickly followed by many additional cases. [42] [22] [23] [24]

In 2002 the United States Food and Drug Administration (FDA) obligated BMS to add a black box warning about potential fatal liver toxicity to the drug label. [43] [13] Worldwide sales in 2002 were $409 million. [39]

In 2003 Public Citizen filed a citizen petition asking the FDA to withdraw the marketing authorization in the United States, and in early 2004 the organization sued the FDA to attempt to force withdrawal of the drug. [43] [44] The FDA issued a response to the petition in June 2004 and filed a motion to dismiss, and Public Citizen withdrew the suit. [44]

Sales of nefazodone were about $100 million in 2003. [45] By that time, it was also being marketed under the additional brand names Serzonil, Nefadar, and Rulivan. [7]

Generic versions were introduced in the United States in 2003 [12] and Health Canada withdrew the marketing authorization that same year. [46]

In April 2004, BMS announced that it was going to discontinue the sale of Serzone in the United States in June 2004 and said that this was due to declining sales and generic versions were available in the United States. [12] [13] [45] By that time, BMS had already withdrawn the drug from the market in Europe, Australia, New Zealand, and Canada. [13]

In August 2020, Teva Pharmaceuticals placed nefazodone in shortage due to a shortage of a raw ingredient. On December 20, 2021, nefazodone was again made available in all strengths. [8] [47]

Society and culture

Generic names

Nefazodone is the generic name of the drug and its INN Tooltip International Nonproprietary Name and BAN Tooltip British Approved Name, while néfazodone is its DCF Tooltip Dénomination Commune Française and nefazodone hydrochloride is its USAN Tooltip United States Adopted Name and USP Tooltip United States Pharmacopeia. [4] [5] [48] [6]

Brand names

Nefazodone has been marketed under a number of brand names including Dutonin (AT Tooltip Austria, ES Tooltip Spain, IE Tooltip Ireland, UK Tooltip United Kingdom), Menfazona (ES Tooltip Spain), Nefadar (CH Tooltip Switzerland, DE Tooltip Germany, NO Tooltip Norway, SE Tooltip Sweden), Nefazodone BMS (AT Tooltip Austria), Nefazodone Hydrochloride Teva (US Tooltip United States), Reseril (IT Tooltip Italy), Rulivan (ES Tooltip Spain), and Serzone (AU Tooltip Australia, CA Tooltip Canada, US Tooltip United States). [5] [6]

Research

Nefazodone was under development for the treatment of panic disorder, and reached phase 3 clinical trials for this indication, but development was discontinued in 2004. [49]

The use of nefazodone to prevent migraine has been studied, due to its antagonism of the serotonin 5-HT2A and 5-HT2C receptors. [50] [51] [52]

Related Research Articles

<span class="mw-page-title-main">Sertraline</span> Antidepressant (SSRI class) medication

Sertraline, sold under the brand name Zoloft among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. The effectiveness of sertraline for depression is similar to that of other antidepressants, and the differences are mostly confined to side effects. Sertraline is better tolerated than the older tricyclic antidepressants. Sertraline is effective for panic disorder, social anxiety disorder, generalized anxiety disorder (GAD), and obsessive–compulsive disorder (OCD). Although approved for post-traumatic stress disorder (PTSD), sertraline leads to only modest improvement in this condition. Sertraline also alleviates the symptoms of premenstrual dysphoric disorder (PMDD) and can be used in sub-therapeutic doses or intermittently for its treatment.

<span class="mw-page-title-main">Mirtazapine</span> Antidepressant medication

Mirtazapine, sold under the brand name Remeron among others, is an atypical tetracyclic antidepressant, and as such is used primarily to treat depression. Its effects may take up to four weeks, but can also manifest as early as one to two weeks. It is often used in cases of depression complicated by anxiety or insomnia. The effectiveness of mirtazapine is comparable to other commonly prescribed antidepressants. It is taken by mouth.

<span class="mw-page-title-main">Buspirone</span> Medication used to treat anxiety disorders


Buspirone, sold under the brand name Buspar, among others, is an anxiolytic, a medication primarily used to treat anxiety disorders, particularly generalized anxiety disorder. It is a serotonin 5-HT1A receptor agonist, increasing action at serotonin receptors in the brain. It is taken orally, and takes two to six weeks to be fully effective.

<span class="mw-page-title-main">Amoxapine</span> Tricyclic antidepressant medication

Amoxapine, sold under the brand name Asendin among others, is a tricyclic antidepressant (TCA). It is the N-demethylated metabolite of loxapine. Amoxapine first received marketing approval in the United States in 1980, approximately 10 to 20 years after most of the other TCAs were introduced in the United States.

<span class="mw-page-title-main">Desipramine</span> Antidepressant

Desipramine, sold under the brand name Norpramin among others, is a tricyclic antidepressant (TCA) used in the treatment of depression. It acts as a relatively selective norepinephrine reuptake inhibitor, though it does also have other activities such as weak serotonin reuptake inhibitory, α1-blocking, antihistamine, and anticholinergic effects. The drug is not considered a first-line treatment for depression since the introduction of selective serotonin reuptake inhibitor (SSRI) antidepressants, which have fewer side effects and are safer in overdose.

<span class="mw-page-title-main">Doxepin</span> Medication to treat depressive disorder, anxiety disorders, chronic hives, and trouble sleeping

Doxepin is a medication belonging to the tricyclic antidepressant (TCA) class of drugs used to treat major depressive disorder, anxiety disorders, chronic hives, and insomnia. For hives it is a less preferred alternative to antihistamines. It has a mild to moderate benefit for sleeping problems. It is used as a cream for itchiness due to atopic dermatitis or lichen simplex chronicus.

<span class="mw-page-title-main">Viloxazine</span> Medication used to treat ADHD

Viloxazine, sold under the brand name Qelbree and formerly as Vivalan among others, is a selective norepinephrine reuptake inhibitor medication which is used in the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults. It was marketed for almost 30 years as an antidepressant for the treatment of depression before being discontinued and subsequently repurposed as a treatment for ADHD. Viloxazine is taken orally. It was used as an antidepressant in an immediate-release form and is used in ADHD in an extended-release form.

<span class="mw-page-title-main">Trimipramine</span> Antidepressant

Trimipramine, sold under the brand name Surmontil among others, is a tricyclic antidepressant (TCA) which is used to treat depression. It has also been used for its sedative, anxiolytic, and weak antipsychotic effects in the treatment of insomnia, anxiety disorders, and psychosis, respectively. The drug is described as an atypical or "second-generation" TCA because, unlike other TCAs, it seems to be a fairly weak monoamine reuptake inhibitor. Similarly to other TCAs, however, trimipramine does have antihistamine, antiserotonergic, antiadrenergic, antidopaminergic, and anticholinergic activities.

<span class="mw-page-title-main">Trazodone</span> Antidepressant medication

Trazodone, sold under many brand names, is an antidepressant medication. It is used to treat major depressive disorder, anxiety disorders, and insomnia. The medication is taken orally.

<span class="mw-page-title-main">Lofepramine</span> Chemical compound

Lofepramine, sold under the brand names Gamanil, Lomont, and Tymelyt among others, is a tricyclic antidepressant (TCA) which is used to treat depression. The TCAs are so named as they share the common property of having three rings in their chemical structure. Like most TCAs lofepramine is believed to work in relieving depression by increasing concentrations of the neurotransmitters norepinephrine and serotonin in the synapse, by inhibiting their reuptake. It is usually considered a third-generation TCA, as unlike the first- and second-generation TCAs it is relatively safe in overdose and has milder and less frequent side effects.

<i>meta</i>-Chlorophenylpiperazine Stimulant

meta-Chlorophenylpiperazine (mCPP) is a psychoactive drug of the phenylpiperazine class. It was initially developed in the late-1970s and used in scientific research before being sold as a designer drug in the mid-2000s. It has been detected in pills touted as legal alternatives to illicit stimulants in New Zealand and pills sold as "ecstasy" in Europe and the United States.

<span class="mw-page-title-main">Desmetramadol</span> Opioid painkiller medication

Desmetramadol, also known as O-desmethyltramadol (O-DSMT), is an opioid analgesic and the main active metabolite of tramadol. Tramadol is demethylated by the liver enzyme CYP2D6 to desmetramadol in the same way as codeine, and so similarly to the variation in effects seen with codeine, individuals who have a less active form of CYP2D6 will tend to have reduced analgesic effects from tramadol. Because desmetramadol itself does not need to be metabolized to induce an analgesic effect, it can be used in individuals with low CYP2D6 activity unlike tramadol.

<span class="mw-page-title-main">Medifoxamine</span> Withdrawn atypical antidepressant drug

Medifoxamine, previously sold under the brand names Clédial and Gerdaxyl, is an atypical antidepressant with additional anxiolytic properties acting via dopaminergic and serotonergic mechanisms which was formerly marketed in France and Spain, as well as Morocco. The drug was first introduced in France sometime around 1990. It was withdrawn from the market in 1999 (Morocco) and 2000 (France) following incidences of hepatotoxicity.

<span class="mw-page-title-main">Vilazodone</span> Antidepressant medication

Vilazodone, sold under the brand name Viibryd among others, is a medication used to treat major depressive disorder. It is classified as a serotonin modulator and is taken by mouth.

<span class="mw-page-title-main">Lubazodone</span> Chemical compound

Lubazodone is an experimental antidepressant which was under development by Yamanouchi for the treatment for major depressive disorder in the late 1990s and early 2000s but was never marketed. It acts as a serotonin reuptake inhibitor and 5-HT2A receptor antagonist, and hence has the profile of a serotonin antagonist and reuptake inhibitor (SARI). The drug has good selectivity against a range of other monoamine receptors, with its next highest affinities being for the α1-adrenergic receptor and the 5-HT2C receptor. Lubazodone is structurally related to trazodone and nefazodone, but is a stronger serotonin reuptake inhibitor and weaker as a 5-HT2A receptor antagonist in comparison to them and is more balanced in its actions as a SARI. It reached phase II clinical trials for depression, but development was discontinued in 2001 reportedly due to the "erosion of the SSRITooltip selective serotonin reuptake inhibitor market in the United States".

<span class="mw-page-title-main">Serotonin antagonist and reuptake inhibitor</span> Class of drug

Serotonin antagonist and reuptake inhibitors (SARIs) are a class of drugs used mainly as antidepressants, but also as anxiolytics and hypnotics. They act by antagonizing serotonin receptors such as 5-HT2A and inhibiting the reuptake of serotonin, norepinephrine, and/or dopamine. Additionally, most also antagonize α1-adrenergic receptors. The majority of the currently marketed SARIs belong to the phenylpiperazine class of compounds.

<span class="mw-page-title-main">Levomilnacipran</span> SNRI antidepressant drug

Levomilnacipran is an antidepressant which was approved in the United States in 2013 for the treatment of major depressive disorder (MDD) in adults. It is the levorotatory enantiomer of milnacipran, and has similar effects and pharmacology, acting as a serotonin–norepinephrine reuptake inhibitor (SNRI).

<span class="mw-page-title-main">Triazoledione</span> Phenylpiperazine compound

Triazoledione is a phenylpiperazine compound and a major metabolite of the antidepressant nefazodone. It is active, but with substantially reduced potency compared to nefazodone. As such, it has been suggested that it is unlikely that triazoledione contributes significantly to the pharmacology of nefazodone. However, triazoledione may reach concentrations as great as 10 times those of nefazodone, and hence could still be a significant contributor to its therapeutic effects.

<span class="mw-page-title-main">Hydroxynefazodone</span> Chemical compound

Hydroxynefazodone is a phenylpiperazine compound and a major metabolite of the antidepressant nefazodone. It has similar biological activity and a similar elimination half-life to those of nefazodone, and may contribute significantly to its effects.

References

  1. ↑ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Schatzberg AF, Nemeroff CB (2017). The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition. American Psychiatric Pub. pp. 460–. ISBN   978-1-58562-523-9.
  3. 1 2 3 4 Pacifici GM, Pelkonen O (24 May 2001). Interindividual Variability in Human Drug Metabolism. CRC Press. pp. 103–. ISBN   978-0-7484-0864-1.
  4. 1 2 Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 857–. ISBN   978-1-4757-2085-3.
  5. 1 2 3 Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 722–. ISBN   978-3-88763-075-1.
  6. 1 2 3 "Nefazodone International Brands". Drugs.com. Archived from the original on 1 December 2017. Retrieved 1 June 2017.
  7. 1 2 3 4 5 "Drugs of Current Interest: Nefazodone". WHO Pharmaceuticals Newsletter (1). 2003. Archived from the original on April 3, 2015.
  8. 1 2 "Teva Nefazodone Statement". www.tevausa.com. 20 December 2021. Archived from the original on 2022-01-23. Retrieved 2022-01-23.
  9. 1 2 3 4 5 "Serzone (Nefazodone): Side Effects, Interactions, Warning, Dosage & Uses". RxList. January 2005. Archived from the original on 6 June 2017. Retrieved 3 June 2017.
  10. 1 2 Ellingrod VL, Perry PJ (December 1995). "Nefazodone: a new antidepressant". Am J Health Syst Pharm. 52 (24): 2799–812. doi:10.1093/ajhp/52.24.2799. PMID   8748566.
  11. 1 2 3 Babai S, Auclert L, Le-Louët H (2021). "Safety data and withdrawal of hepatotoxic drugs". Therapie. 76 (6): 715–723. doi:10.1016/j.therap.2018.02.004. PMID   29609830.
  12. 1 2 3 "Nefazodone". Drug Patent Watch. Archived from the original on 27 January 2018. Retrieved 3 June 2017.
  13. 1 2 3 4 Cosgrove-Mather B (April 15, 2004). "Anti-Depressant Taken Off Market". CBS News. Archived from the original on December 2, 2020. Retrieved June 3, 2017.
  14. ↑ "Drugs@FDA: FDA-Approved Drugs". Archived from the original on 2021-08-27. Retrieved 2023-02-11.
  15. ↑ "DailyMed - NEFAZODONE HYDROCHLORIDE tablet". dailymed.nlm.nih.gov. Archived from the original on 2016-09-16. Retrieved 2023-10-29.
  16. ↑ "List of 54 Anxiety Medications Compared". Drugs.com. Archived from the original on 2022-01-23. Retrieved 2022-01-23.
  17. ↑ Nefazodone. LiverTox (NIDDK). 2 June 2017. PMID   31643176. Archived from the original on 2 July 2019. Retrieved 3 June 2017.
  18. 1 2 "Nefazodone Package insert / prescribing information". Drugs.com. Archived from the original on 2020-08-09. Retrieved 2017-11-24.
  19. ↑ Sussman N, Ginsberg DL, Bikoff J (April 2001). "Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials". The Journal of Clinical Psychiatry. 62 (4): 256–260. doi:10.4088/JCP.v62n0407. PMID   11379839.
  20. ↑ Ferguson JM, Shrivastava RK, Stahl SM, Hartford JT, Borian F, Ieni J, et al. (January 2001). "Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline". The Journal of Clinical Psychiatry. 62 (1): 24–29. doi:10.4088/jcp.v62n0106. PMID   11235924.
  21. ↑ Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F (2001). "Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction". The Journal of Clinical Psychiatry. 62 (Suppl 3): 10–21. PMID   11229449. Archived from the original on 2022-12-17. Retrieved 2022-12-17.
  22. 1 2 Edwards IR (April 2003). "Withdrawing drugs: nefazodone, the start of the latest saga". Lancet. 361 (9365): 1240. doi:10.1016/S0140-6736(03)13030-9. PMID   12699949. S2CID   39993080.
  23. 1 2 Choi S (November 2003). "Nefazodone (Serzone) withdrawn because of hepatotoxicity". CMAJ. 169 (11): 1187. PMC   264962 . PMID   14638657.
  24. 1 2 3 Stewart DE (May 2002). "Hepatic adverse reactions associated with nefazodone". Canadian Journal of Psychiatry. 47 (4): 375–377. doi: 10.1177/070674370204700409 . PMID   12025437.
  25. ↑ "Nefazodone hydrochloride - Drug Summary". PDR.net. Archived from the original on 2022-10-12. Retrieved 2022-10-12.
  26. ↑ Lexi-Comp (September 2008). "Nefazodone". The Merck Manual Professional . Archived from the original on 2010-09-04. Retrieved 2008-11-29. Retrieved on November 29, 2008.
  27. ↑ Spina E, Santoro V, D'Arrigo C (July 2008). "Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update". Clinical Therapeutics. 30 (7): 1206–1227. doi:10.1016/S0149-2918(08)80047-1. PMID   18691982.
  28. ↑ Richelson E (September 1997). "Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs". Mayo Clinic Proceedings. 72 (9): 835–847. doi: 10.4065/72.9.835 . PMID   9294531.
  29. ↑ Roth BL, Driscol J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Archived from the original on 28 October 2021. Retrieved 14 August 2017.
  30. 1 2 3 4 5 Tatsumi M, Groshan K, Blakely RD, Richelson E (December 1997). "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". European Journal of Pharmacology. 340 (2–3): 249–258. doi:10.1016/s0014-2999(97)01393-9. PMID   9537821.
  31. 1 2 3 4 Owens MJ, Morgan WN, Plott SJ, Nemeroff CB (December 1997). "Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites". The Journal of Pharmacology and Experimental Therapeutics. 283 (3): 1305–1322. PMID   9400006.
  32. 1 2 3 4 5 6 7 8 9 10 Cusack B, Nelson A, Richelson E (May 1994). "Binding of antidepressants to human brain receptors: focus on newer generation compounds". Psychopharmacology. 114 (4): 559–565. doi:10.1007/bf02244985. PMID   7855217. S2CID   21236268.
  33. 1 2 3 4 Roth BL, Kroeze WK (2006). "Screening the receptorome yields validated molecular targets for drug discovery". Current Pharmaceutical Design. 12 (14): 1785–1795. doi:10.2174/138161206776873680. PMID   16712488.
  34. ↑ Sánchez C, Hyttel J (August 1999). "Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding". Cellular and Molecular Neurobiology. 19 (4): 467–489. doi:10.1023/A:1006986824213. PMID   10379421. S2CID   19490821.
  35. 1 2 3 Preskorn SH, Stanga CY, Feighner JP, Ross R (6 December 2012). Antidepressants: Past, Present and Future. Springer Science & Business Media. pp. 68–. ISBN   978-3-642-18500-7.
  36. ↑ Davis R, Whittington R, Bryson HM (April 1997). "Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression". Drugs. 53 (4): 608–636. doi:10.2165/00003495-199753040-00006. PMID   9098663. S2CID   239077479.
  37. 1 2 Eison MS, Taylor DB, Riblet LA (1987). "Atypical Psychotropic Agents". In Williams M, Malick JB (eds.). Drug Discovery and Development. Springer Science & Business Media. p. 390. ISBN   978-1-4612-4828-6.
  38. ↑ Associated Press (16 March 2004). "Consumer group seeks ban on antidepressant". NBC News. Archived from the original on 24 September 2020. Retrieved 3 June 2017.
  39. 1 2 Hoffmann C (January 8, 2003). "Bristol-Myers to withdraw Dutonin in Europe". First Word Pharma. Archived from the original on September 12, 2017. Retrieved June 3, 2017.
  40. ↑ Aranda-Michel J, Koehler A, Bejarano PA, Poulos JE, Luxon BA, Khan CM, et al. (February 1999). "Nefazodone-induced liver failure: report of three cases". Ann Intern Med. 130 (4 Pt 1): 285–8. doi:10.7326/0003-4819-130-4-199902160-00013. PMID   10068386.
  41. ↑ Schrader GD, Roberts-Thompson IC (May 1999). "Adverse effect of nefazodone: hepatitis". Med J Aust. 170 (9): 452. doi:10.5694/j.1326-5377.1999.tb127827.x. PMID   10341782. S2CID   1907139.
  42. ↑ DeSanty KP, Amabile CM (July 2007). "Antidepressant-induced liver injury". Ann Pharmacother. 41 (7): 1201–11. doi:10.1345/aph.1K114. PMID   17609231. S2CID   24974828.
  43. 1 2 "Public Citizen to sue FDA over Serzone - Pharmaceutical industry news". The Pharma Letter. 22 March 2004. Archived from the original on 5 August 2020. Retrieved 3 June 2017.
  44. 1 2 "Court Decisions and Updates" (PDF). FDA. Archived (PDF) from the original on 10 May 2017. Retrieved 3 June 2017.
  45. 1 2 DeNoon DJ (May 4, 2004). "Company Pulls Antidepressant Off Market". WebMD. Archived from the original on September 12, 2017. Retrieved June 3, 2017.
  46. ↑ Lexchin J (March 2005). "Drug withdrawals from the Canadian market for safety reasons, 1963-2004". CMAJ. 172 (6): 765–767. doi:10.1503/cmaj.045021. PMC   552890 . PMID   15767610.
  47. ↑ "FDA Drug Shortages". www.accessdata.fda.gov. Archived from the original on 2024-01-17. Retrieved 2022-01-23.
  48. ↑ Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 190–. ISBN   978-94-011-4439-1. Archived from the original on 10 January 2023. Retrieved 24 November 2017.
  49. ↑ "Nefazodone - AdisInsight". Archived from the original on 2023-02-12. Retrieved 2023-02-12.
  50. ↑ Saper JR, Lake AE, Tepper SJ (May 2001). "Nefazodone for chronic daily headache prophylaxis: an open-label study". Headache. 41 (5): 465–474. doi:10.1046/j.1526-4610.2001.01084.x. PMID   11380644. S2CID   32785110.
  51. ↑ Mylecharane EJ (1991). "5-HT2 receptor antagonists and migraine therapy". Journal of Neurology. 238 (Suppl 1): S45–S52. doi:10.1007/BF01642906. PMID   2045831. S2CID   5941834.
  52. ↑ Millan MJ (2005). "Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies". Therapie. 60 (5): 441–460. doi:10.2515/therapie:2005065. PMID   16433010.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.